Human papillomavirus 16 (HPV16) is a high‑risk oncogenic type of human papillomavirus that infects mucosal epithelial cells. It is responsible for about half of all cervical cancers worldwide and contributes to cancers of the vagina, vulva, penis, anus and oropharynx. HPV16 is a circular double‑stranded DNA virus in the Papillomaviridae family.
Virology and Oncogenic Mechanisms
HPV16 belongs to the alpha‑9 species of papillomaviruses and has an approximately 7.9 kb circular double‑stranded DNA genome with early (E) and late (L) open reading frames. The early region encodes proteins for replication and regulation (E1, E2), immune modulation (E4, E5) and the oncoproteins E6 and E7, while the late region encodes the structural proteins L1 and L2. The virus infects basal epithelial cells through microscopic abrasions and initially maintains its genome as an episome. Viral gene expression is linked to cellular differentiation, with assembly of virions occurring in the superficial layers. Persistent infection can lead to integration of the viral genome into the host chromosome, usually disrupting the E2 gene and allowing uncontrolled expression of E6 and E7. E6 promotes degradation of the p53 tumour suppressor through ubiquitin‑mediated proteolysis and activates telomerase, while E7 binds and inactivates the retinoblastoma protein, releasing E2F transcription factors and driving cells into the S phase. These interactions deregulate cell cycle control, promote genomic instability and are central to malignant transformation. HPV16 also modulates innate immune signalling and antigen presentation to evade host defences. Factors such as smoking, long‑term oral contraceptive use, co‑infection with other sexually transmitted pathogens and immunosuppression increase the likelihood of progression to high‑grade lesions, although most infections are cleared by cell‑mediated immunity within a few years.
Disease Associations and Prevention
HPV16 is the predominant type detected in cervical cancer and high‑grade cervical intraepithelial neoplasia. It is also implicated in cancers of the oropharynx (particularly the tonsils and base of tongue), anus, vulva, vagina and penis. Precursor lesions include cervical intraepithelial neoplasia grades 2/3 and anal intraepithelial neoplasia. HPV16 is rarely associated with external genital warts, which are usually caused by low‑risk types. The prevalence of HPV16 infection peaks soon after the onset of sexual activity. Prevention strategies focus on vaccination with the L1 virus‑like particle vaccines. The bivalent, quadrivalent and nonavalent HPV vaccines all contain HPV16 and provide strong protection against infection and cervical precancer; the nonavalent formulation also covers additional high‑risk types (18, 31, 33, 45, 52 and 58) and low‑risk types 6 and 11. Cervical screening using Papanicolaou smears and HPV DNA testing enables early detection and treatment of precancerous lesions with excisional or ablative procedures. Regular screening is critical even for vaccinated individuals because vaccines do not protect against all oncogenic types. Condom use lowers the risk of transmission but does not eliminate it because HPV can infect areas not covered by condoms. HPV16 is the most common oncogenic papillomavirus and a major cause of cervical and other anogenital and oropharyngeal cancers. Its pathogenicity stems from its E6 and E7 oncoproteins, which disrupt key tumour suppressors following viral integration. Vaccination, routine screening and safe sexual practices are essential for preventing infection and reducing the burden of HPV16‑related disease. Related Terms: Oncogenic HPV, Cervical intraepithelial neoplasia, E6 protein, E7 protein, HPV18